Arcellx News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.12.24	In-Depth Examination Of 14 Analyst Recommendations For Arcellx (Benzinga)
09.12.24	14 Analysts Have This To Say About Arcellx (Benzinga)
06.11.24	Navigating 7 Analyst Ratings For Arcellx (Benzinga)
22.10.24	Cracking The Code: Understanding Analyst Reviews For Arcellx (Benzinga)
18.10.24	4 Analysts Assess Arcellx: What You Need To Know (Benzinga)
21.09.24	FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks (RTTNews)
19.09.24	ACLX, HROW Deliver Triple-Digit Returns - Did You Cash In? (RTTNews)
09.08.24	Assessing Arcellx: Insights From 7 Financial Analysts (Benzinga)
22.07.24	Decoding 8 Analyst Evaluations For Arcellx (Benzinga)
18.06.24	The Latest Analyst Ratings For Arcellx (Benzinga)
31.05.24	Expert Ratings For Arcellx (Benzinga)
29.02.24	Arcellx Analysts Boost Their Forecasts After Q4 Results (Benzinga)
04.01.24	Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 (Benzinga)
04.01.24	Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know (Benzinga)
08.12.23	Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH (PR Newswire)
15.11.23	Gilead's Kite, Arcellx Expand Partnership (RTTNews)
02.11.23	Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition (PR Newswire)
16.08.23	Arcellx: Partial Clinical Hold Lifted By FDA On IMMagine-1 Phase 2 Trial; Q2 Net Loss Narrows (RTTNews)
20.06.23	Arcellx : FDA Places Clinical Hold On CART-ddBCMA IND For Treatment Of R/R Multiple Myeloma (RTTNews)
20.06.23	Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program (PR Newswire)
27.04.23	Biotech Stocks That Hit New Highs Yesterday (RTTNews)
26.04.23	Did You Catch These Biotech High-Flyers Before They Hit New Highs Yesterday? (RTTNews)
13.04.23	Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference (PR Newswire)
21.02.23	Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference (PR Newswire)
02.02.23	Arcellx to Participate in Upcoming Investor Conferences (PR Newswire)
09.12.22	Arcellx Announces Positive Response From CART-dd BCMA Phase 1 Trial Of ACLX-002 In Multiple Myeloma (RTTNews)
09.12.22	Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress (PR Newswire)
09.12.22	Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma (PR Newswire)
15.08.22	Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results (PR Newswire)
21.06.22	Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel (PR Newswire)
21.06.22	Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares (PR Newswire)
16.06.22	Arcellx Prices Underwritten Follow-on Offering Of 7 Mln Shares At $16.00/shr (RTTNews)
16.06.22	Arcellx Announces Upsizing and Pricing of Follow-On Public Offering (PR Newswire)
03.06.22	Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting (PR Newswire)
23.05.22	Arcellx Appoints Michelle Gilson as Chief Financial Officer (PR Newswire)
16.05.22	Arcellx Appoints Olivia Ware to Board of Directors (PR Newswire)
12.05.22	Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results (PR Newswire)
10.05.22	Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients... (PR Newswire)
09.05.22	Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma (PR Newswire)
05.05.22	Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference (PR Newswire)
27.04.22	Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinica... (PR Newswire)
08.04.22	Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Resear... (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Arcellx Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten